Key facts
- It has raised $18.8M across 2 recorded rounds; the latest was Early Stage VC ($7.6M) in Nov 2023.
- Notable investors include The Engine, Safar Partners, Engine Ventures, Labcorp Venture Fund, Ideaship — 7 tracked in total.
- Droplet Biosciences has filed 2 Form Ds with the SEC since 2021, most recently Dec 2023 ($7.6M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Droplet Biosciences
Funding rounds
2 roundsAbout Droplet Biosciences
Operator of a molecular diagnostics company intended to improve cancer care through lymph liquid biopsy. The company provides sensitive cancer diagnostics with non-invasive liquid biopsy techniques, enabling healthcare professionals to aid in post-operative treatment decisions, enabling healthcare professionals to make more precise adjuvant care decisions after cancer surgery.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 19
- Website
- dropletbiosci.com/
- Ownership
- Privately Held (backing)
Droplet Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Droplet Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Droplet Biosciences in its N-PORT filings yet. We sweep new filings monthly.